


PRODUCT INFORMATION



Pseudolaric Acid B

Item No. 13527

CAS Registry No.: 82508-31-4
Formal Name: (3R,4S,4aS,9aR)-4a-(acetyloxy)-3-[(1E,3E)-4-carboxy-1,3-pentadien-1-yl]-3,4,4a,5,6,9-hexahydro-3-methyl-1-oxo-1H-4,9a-ethanocyclohepta[c]pyran-7-carboxylic acid, 7-methyl ester
Synonyms: NSC 615488, PAB
MF: C₂₃H₂₈O₈
FW: 432.5
Purity: ≥98%
UV/Vis.: λ_{max}: 258 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥4 years
Item Origin: Plant/*Pseudolarix amabilis* (J. Nelson) Rehd.



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Pseudolaric acid B (PAB) is supplied as a crystalline solid. A stock solution may be made by dissolving the PAB in the solvent of choice, which should be purged with an inert gas. PAB is soluble in organic solvents such as ethanol, DMSO, and chloroform. The solubility of PAB in these solvents is approximately 10 mg/ml.

Description

PAB is a diterpene acid isolated from the bark of *P. kaempferi*, a traditional Chinese medicinal plant. It has reported antifungal activities, consistent with its traditional use in the treatment of dermatological fungal infections.¹ Moreover, PAB has diverse effects that are relevant to cancer therapy, including inducing apoptosis of cancer cells (IC₅₀ = ~1 μM), preventing angiogenesis, and inhibiting tumor growth *in vivo*.²⁻⁴

References

1. Li, E., Clark, A.M., and Hufford, C.D. Antifungal evaluation of pseudolaric acid B, a major constituent of *Pseudolarix kaempferi*. *J. Nat. Prod.* **58(1)**, 57-67 (1995).
2. Gong, X., Wang, M., Tashiro, S.i., *et al.* Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death. *Exp. Mol. Med.* **38(4)**, 428-434 (2006).
3. Wong, V.K.W., Chiu, P., Chung, S.S.M., *et al.* Pseudolaric acid B, a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity *in vivo*. *Clin. Cancer Res.* **11(16)**, 6002-6011 (2005).
4. Li, M.H., Miao, Z.H., Tan, W.F., *et al.* Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1α by promoting proteasome-mediated degradation. *Clin. Cancer Res.* **10(24)**, 8266-8274 (2004).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the complete Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 10/10/2022

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897

[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM

WWW.CAYMANCHEM.COM